![Show Menu](styles/mobile-menu.png)
![Page Background](./../common/page-substrates/page0007.png)
Note:
Page 17
July 18-19, 2019 | Valencia, Spain
OF EXCELLENCE
IN INTERNATIONAL
MEETINGS
alliedacademies.comYEARS
Asian Journal of Biomedical and Pharmaceutical Sciences
ISSN: 2249-622X | Volume 9
Pharma Summit 2019
2
nd
GLOBAL PHARMA SUMMIT
ULTRA PERFORMANCE LIQUID CHROMATOGRAPHIC METHOD DEVELOPMENT AND
VALIDATION FOR THE DETERMINATION OF GLECAPREVIR AND PIBRENTASVIR IN
PHARMACEUTICAL DOSAGE FORMS
Poojitha Dhulipalla
Vimta Labs Ltd., India
T
he combination of Glecaprevir and Pibrentasvir is used to treat certain types of chronic hepatitis C infection.
A new analytical method was developed and validated for the simultaneous determination of the Gleca-
previr and Pibrentasvir in pharmaceutical dosage form by using UPLC. In this method, Chromatogram was run
through HSSC18 (1.8μm 2.1x 100mm) column, mobile phase containing Potassium dihydrogen orthophos-
phate buffer (Adjusted using 30% v/v of ortho phosphoric acid pH 3.5) and Acetonitrie in the ratio of 30:70
was pumped through column at a flow rate of 0.3ml/min. Temperature was maintained at 30°C. Optimized
wavelength for Glecaprevir and Pibrentasvir was 260nm. Retention times of Glecaprevir and Pibrentasvir were
found to be 0.61min and 0.92min. The total run time was 2.0min. The percentage recovery was obtained as
98.4 and 99.2% for Glecaprevir and Pibrentasvir respectively. The developed method was validated as per ICH
guidelines and hence it can be used for the routine analysis in various pharmaceutical industries and drug
testing laboratories.
Poojitha Dhulipalla, Asian J Biomed Pharmaceut Sci 2019, Volume 9
Poojitha Dhulipalla has completed her M Pharmacy from JSS University, Ooty, India. She is having two years of experience as audi-
tor in the Quality Assurance Department in Pharmaceutical industry. She has over 10 publications in various reputed journals and
attended various national and international conferences.
sobhapoojitha009@gmail.comBIOGRAPHY